Ask AI
HER2 Altered NSCLC

CE / CME

HER2-Directed ADCs in HER2-Mutant and HER2-Overexpressing NSCLC

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: March 18, 2026

Expiration: September 17, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology. 2009;21:177-184.
  2. Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precision Oncology. 2020;4:411-425.
  3. Boch T, Köhler J, Janning M, et al. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. Cancer Biol Med. 2022;19:1543-1564.
  4. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491-1505.
  5. Ren S, Wang J, Ying J, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022;7:100395.
  6. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.5.2026. nccn.org. Accessed March 16, 2026.
  7. Uzunparmak B, Haymaker C, Raso G, et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol. 2023;34:1035-1046.
  8. Yu X, Ji X, Su C. HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies. Front Oncol. 2022;12:860313.
  9. Nützinger J, Lee JB, Low JL, et al. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung Cancer. 2023;186:107385.
  10. Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26:1421-1427.
  11. Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189-194.
  12. Gandhi L, Besse B, Mazieres J, et al. Neratinib ± temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study. Presented at: 2017 World Conference on Lung Cancer Annual Conference; October 15-18, 2017. Abstract MA04.02.
  13. Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14:1086-1094.
  14. Peters S, Curioni-Fontecedro A, Nechushtan H, et al. Activity of afatinib in heavily pretreated patients with ERBB2 mutation–positive advanced NSCLC: findings from a global named patient use program. J Thorac Oncol. 2018;13:1897-1905.
  15. Afatinib [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; 2022.
  16. Dacomitinib [prescribing information]. New York, NY: Pfizer; 2018.
  17. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532-2537.
  18. Mazières J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27:281-286.
  19. Liu D, Makker V, Buonocore DJ, et al. Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers. Presented at: 2023 American Society of Clinical Oncology Annual Conference; June 2-6, 2023. Abstract 3025.
  20. Sweeney CJ, Hainsworth JD, Bose R, et al. MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2–altered advanced solid tumors. J Clin Oncol. 2023;42:258-265.
  21. Zongertinib [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; 2025.
  22. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2024.
  23. Sevabertinib [prescribing information]. Whippany, NJ: Bayer HealthCare; 2025.
  24. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173-185.
  25. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097-5108.
  26. Birrer MJ, Moore KN, Betella I, et al. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538-549.
  27. Chen H, Lin Z, Arnst K, et al. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22:1281.
  28. Indini A, Rijavec E, Grossi F. Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci. 2021;22:4774.
  29. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24:5357-5363.
  30. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225.
  31. Diamantis N, Banerji U. Antibody-drug conjugates—an emerging class of cancer treatment. British J Cancer. 2016;114:362-367.
  32. Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.
  33. Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, et al. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11:3-23.
  34. Coats S, Williams M, Kebble B, et al. Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25:5441-5448.
  35. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386:241-251.
  36. Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25:439-454.
  37. Jänne PA, Goto Y, Kubo T, et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer. J Thorac Oncol. 2025;20:1814-1828.
  38. Thompson M and Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res. 2019;8:48-47.
  39. Jänne PA, Planchard D, Goto K, et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials. JAMA Network Open. 2025;8:e2543107.
  40. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47-58.
  41. Cheng Y, Li D, Wu L, et al. Trastuzumab deruxtecan in patients from China with pretreated HER2-mutant NSCLC: final results from the DESTINY-Lung05 study. J Thorac Oncol. 2025;20:S376-S377.
  42. Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852-4863.
  43. Janne PA. Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study. Future Oncol. 2026;22:659-670.
  44. Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates. JAMA Oncol. 2021;7:1873-1881.
  45. Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7:100554.
  46. Rugo HS, Bianchini G, Cortes J, et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7:100553.
  47. Chiu J, Lee SC, Ho JC-M, et al. Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel. Drug Saf. 2023;46:927-949.
  48. Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in previously treated HER2-mutant non–small-cell lung cancer. N Engl J Med. 2025;392:2321-2333.
  49. Le X, Kim TM, Loong HH, et al. Sevabertinib in advanced HER2-mutant non–small-cell lung cancer. N Engl J Med. 2025;393:1819-1832.
  50. Zeng H, Wang W, Zhang L, et al. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs. Cancer Drug Resist. 2024;7:14.
  51. Planchard D, Kim HR, Suksombooncharoen T, et al. Trastuzumab deruxtecan in patients With HER2-overexpressing NSCLC: results from part 1 of the open-label, multicenter, phase 1b DESTINY-Lung03 trial. J Thorac Oncol. 2025;[Epub ahead of print].